The researchers evaluated budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol in preventing COPD exacerbations and pneumonia hospitalizations in real-world settings. They ...

JERUSALEM--(BUSINESS WIRE)--Mar. 9, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the launch of the generic equivalent to Pulmicort Respules®1 (budesonide inhalation ...

AstraZeneca will discontinue the production of PULMICORT® (budesonide) 100 and 200 µg/dose HFA pMDI (pressurised metered dose inhaler) due to complex manufacturing issues related to technical aspects ...

If budesonide-formoterol were to become available over the counter (OTC) and used as-needed for mild asthma, it would save lives and cut healthcare costs, according to a computer modeling study ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...

The management of asthma has changed since the introduction of budesonide/formoterol (Symbicort ®) as both maintenance and reliever therapy (SMART). SMART and its effects on bronchial ...

In extremely preterm infants (<28 weeks) does treatment with early inhaled budesonide, compared to placebo, affect neurodevelopmental outcomes at 2 years of age? Patients: The study population ...

Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...

Inhaled budesonide (Pulmicort), commonly used in asthma, helped COVID-19 outpatients at extra risk for severe illness recover more quickly relative to standard care in the pragmatic PRINCIPLE trial, ...

Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

Sept. 28, 2005 ( updated Oct. 6, 2005) -- The U.S. Food and Drug Administration (FDA) approved safety labeling revisions in June to advise that doxercalciferol dose reductions are recommended in ...